Investment Stage

Focus Areas

About Investor

Malek Faham serves as Venture Partner at Illumina Ventures, focusing on investments in BioTech, Diagnostics, and Health IT across seed and Series A stages with investment ranges between $500K and $10.0M. His professional background includes extensive experience as an inventor and entrepreneur, having co-founded and served as Chief Scientific Officer of Sequenta (acquired by Adaptive Biotechnologies in 2015) and co-founded ParAllele Biosciences (acquired by Affymetrix for $120M in 2005). Faham holds an MD and Ph.D. in Human Genetics from the University of California, San Francisco, with 60 peer-reviewed articles and 40 US patents to his name, bringing deep scientific and entrepreneurial expertise to his role in the San Francisco Bay Area.